Thomas J. Griffin, Ph.D. is the Research Director at Matrivax Research and Development Corporation. At the University of Colorado, Boulder, Dr. Griffin earned a B.A. magna cum laude in Molecular, Cellular, and Developmental Biology and a B.A. in Biochemistry. His Ph.D. is from the Department of Molecular Genetics and Microbiology at Harvard University and his post-doctoral training was done in the Division of Cellular and Molecular Biology at the Dana-Farber Cancer Institute. Dr. Griffin was head of the Strain Development Group at Baxter Hemoglobin Therapeutics (Somatogen, Inc.) in Boulder, Colorado. In the Department of Biophysics and Biochemistry at Yale University, Dr. Griffin was a member of the Core Facility as a departmental advisor on matters of protein expression and purification, bacterial genetics, and molecular biology as they related to structural and biophysical research. Dr. Griffin joined Dr. John Mekalanos’ laboratory at Harvard Medical School to join early work on the PCMV project prior to the establishment of Matrivax. Dr. Griffin has expertise in the areas of protein expression and purification, protein biochemistry, bacterial genetics, fermentation and microbial physiology.